Maravai Lifesciences Holdings Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -34.4% | -2.9% | +0.2% | -11.7% | -21.1% | -4.8% | -6.5% | -5.3% | -9.3% | -7.4% | -15.3% | |
| – | -0.1% | -4.6% | +2.6% | -0.9% | -36.8% | -12.3% | -4.4% | -9.4% | -9.1% | -15.0% | -38.2% | |
| – | -0.8% | -2.3% | +2.0% | +0.9% | -44.2% | -11.6% | -5.3% | -9.8% | -11.0% | -23.5% | -57.8% | |
| – | -0.8% | -2.3% | +2.0% | +0.9% | -44.2% | -11.6% | -5.3% | -9.8% | -11.0% | -23.5% | -57.8% | |
| – | +13.3% | -29.1% | -0.7% | -26.5% | +33.4% | -26.0% | -2.1% | -19.2% | +13.1% | +31.0% | -6.8% | |
| – | +4.6% | -3.0% | -1.1% | +2.3% | -0.6% | -0.6% | -6.2% | -2.9% | -10.7% | -0.1% | +1.9% | |
| – | +0.0% | +0.0% | +0.0% | -47.3% | -6.9% | +0.0% | -19.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | -3.0% | -3.1% | -3.2% | -2.6% | -3.4% | +2.4% | -3.3% | -3.7% | -18.5% | -4.4% | -4.5% | |
| – | -49.3% | -4.3% | +0.6% | -0.9% | -35.2% | -0.4% | -0.1% | -2.7% | -4.7% | -13.5% | -27.9% | |
| – | +11.8% | -32.5% | +16.1% | -7.7% | -9.9% | +10.9% | +10.3% | -11.6% | -27.1% | -5.1% | -9.9% | |
| – | -2.1% | +1.8% | +1.4% | +1.5% | +1.8% | -54.2% | +0.7% | -13.9% | +0.0% | +0.0% | -79.3% | |
| – | +13.8% | -23.3% | +52.4% | -24.3% | +25.9% | -20.3% | +21.0% | -30.6% | -63.6% | +193.3% | -16.5% | |
| – | -0.2% | -0.2% | -0.2% | -0.2% | -43.7% | -0.3% | -0.4% | -0.4% | -0.4% | -17.7% | -38.0% | |
| – | -19.7% | -1.5% | +6.4% | -21.0% | -5.8% | -7.6% | -11.6% | -7.7% | -13.5% | -0.4% | -3.3% | |
| – | -27.1% | -4.2% | -2.8% | -37.2% | -15.7% | -21.3% | -35.7% | -35.8% | -77.9% | -36.9% | -194.5% | |
| – | +0.2% | +0.1% | +2.7% | +4.2% | -1.3% | +2.6% | +0.6% | +0.3% | +0.3% | +0.9% | +1.1% |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.